


ATC codes: [L01CA01](#)

|                          |  |
|--------------------------|--|
| Indication               | Kaposi sarcoma of unspecified primary site <span>ICD11 code: <a href="#">2C27.Z</a></span>   |
| INN                      | Vinblastine  |
| Medicine type            | Chemical agent   |
| List type                | Complementary  |
| Additional notes         | For intravenous use only   |
| Formulations             | Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) ; 10 mg per 10 mL in vial (vinblastine sulfate)  |
| EML status history       | First added in 2015 ( <a href="#">TRS 994</a> )<br>Changed in 2021 ( <a href="#">TRS 1035</a> )  |
| Sex                      | All  |
| Age                      | Adolescents and adults   |
| Therapeutic alternatives | The recommendation is for this specific medicine   |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |

Tags

Cancer

Wikipedia

[Vinblastine](#) 

DrugBank

[Vinblastine](#) 

### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new formulation of vinblastine IV injection (10 mg/10 mL) to the EML and EMLc.

[Expert Committee report](#) 

